“BioNixus is a global pharmaceutical and healthcare market research company — with proven capability across B2B and B2C sectors. We turn physician, payer, and hospital evidence into launch, market access, and growth decisions for pharmaceutical, biotech, and medtech teams across 48 countries, serving 118 clients in the Americas, EMEA, and APAC.”
“Keep the subscription. Those feeds give you the country total. They typically miss subaccounts, traditional trade, and account-level or SKU-level brand versus competitor breakdowns. BioNixus fields the primary study for that gap. You do not switch vendors — you add the breakdown the dashboard cannot give.”
“BioNixus is a global market research firm founded in London in 2012 in pharmaceutical and healthcare research, now recognised among the world's top 100 market research companies. US-headquartered in Sheridan, Wyoming, with regional leadership offices in London and Cairo and field offices in Al Khobar, Dubai and Kuwait City.”
“The core is healthcare market research: quantitative physician and HCP surveys, qualitative KOL interviews and focus groups, market access and HTA consulting, competitive intelligence, clinical trial support, and KOL and stakeholder mapping. The mix is built around your decision rather than sold as a fixed package, and it runs across 48 countries.”
“We work across 48 countries. Regional leadership offices are in the United States (Sheridan, Wyoming — global headquarters), the United Kingdom (London) and Egypt (Cairo, Sheikh Zayed).”
“No. Pharmaceutical and healthcare research is where BioNixus leads — but the same senior-led methodology extends to B2B and B2C programmes: financial services, real estate, tourism and hospitality, manufacturing, technology, AI startups, retail, and FMCG. Explore the commercial sections below or the BioNixus industries hub for category-specific scope.”
“CAWI suits large-scale online panels and trackers. CATI reaches senior B2B buyers and HCPs who do not respond online. CAPI is essential for on-site audits, hospital visits, and retail mystery programmes. We recommend the mode — or a mixed-mode design — during scoping based on your audience, geography, and timeline.”
“Share your objective, audience, industry, and timeline via the contact form. We typically return a tailored methodology outline within one business day.”
“Technology and B2B software, energy and industrials, real estate and construction, public sector and government, and education — with country pages across the United States, United Kingdom, Germany, Brazil, UAE, Saudi Arabia, and the wider MENA and African markets.”
“B2B studies target a smaller, harder-to-reach population of decision-makers and influencers, weight depth interviews more heavily, and map the full buying committee and procurement pathway rather than mass consumer sentiment.”
“Yes. Modules can run standalone or with comparable cells across GCC, MENA, Africa, Europe, and the Americas using consistent instruments, so cross-market findings stay directly comparable.”
“No. Inclusion and order are editorial and reflect the accounts BioNixus studies most often. Company classification (Local, MNC, Regional, Distributor and so on) describes ownership and role, not size or quality.”
“Each directory names the primary regulator or registry it was checked against (for example the SFDA, MOHAP, EDA, central-bank licensed-bank lists or stock-exchange listings) with an as-of date, plus supporting public sources. Directories are refreshed at least annually and the modification date is shown in the page metadata.”
“Yes. BioNixus runs primary research — customer, prescriber, purchaser, shopper and channel interviews — on named accounts in 48 countries. Use the proposal form on any directory page and name the accounts you need.”
Download this profile and inspect its supporting evidence.